CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 52 enrolled
Drug / intervention
Losartan +1 moredrug
Likely dose
Losartan 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01852942
NCT01852942Phase 2Completed
CompareCT.gov

Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV

University of Minnesota·interventional·Posted May 14, 2013·Updated Dec 11, 2020

In Brief

A Phase 2 clinical trial evaluating Losartan and Placebo for HIV Infection and HIV Infections. Completed, enrolled 52 participants across 1 site.

Detailed Summary

This study was designed to test the hypothesis that treatment of HIV infected subjects with losartan, an agent with specific anti-inflammatory and anti-fibrotic actions, will: 1. reverse existing lymphoid tissue fibrosis, 2. restore lymphoid tissue architecture, 3. increase the number and improve the function of peripheral and lymphatic CD4 T cells, 4. decrease levels of systemic immune activation (IA), 5. decrease size of the HIV reservoir, and 6. be safe and well tolerated.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infection, HIV Infections
CountriesUnited States
CollaboratorsNational Institute of Allergy and Infectious Diseases (NIAID), Merck Sharp & Dohme LLC

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedMay 14, 2013
Enrollment StartSep 1, 2014
Primary CompletionJul 16, 2019
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 13.1 years ago

Interventions

Losartandrug

Participants will start with 50 mg of losartan by mouth daily. The dose will be increased to 100 mg by mouth daily after 14 days. The maximal tolerable dosage (up to 100mg by mouth daily) will be continued for a total of 30 months.

Placebodrug

one tablet by mouth daily